On December 18, 2025, the United States signed the BIOSECURE Act as part of its annual defense authorization law. The legislation restricts federal contracts with Chinese biotechnology firms — WuXi AppTec, WuXi Biologics, and BGI Group among those named — and forces the U.S. pharmaceutical industry to find manufacturing alternatives outside Asia.
For CDMOs and CMOs evaluating where to build or acquire production capacity, that law turned Mexico into a conversation that can no longer be deferred.
The problem is that most available analysis on contract pharmaceutical manufacturing in Mexico swings between government press-release enthusiasm and trend-piece vagueness. This article tries to do something different: put the numbers on the table.
Why Mexico Is on the Shortlist Now
Mexico’s pharmaceutical manufacturing market is valued at between USD 7 billion and USD 8 billion according to CANIFARMA and INEGI, and the sector exports approximately USD 2.3 billion per year. Those figures sound reasonable until you compare them against context: Mexico accounts for just 1.5% of U.S. pharmaceutical imports (Wilson Center, 2024) and runs a pharmaceutical trade deficit of around USD 5.9 billion. Fifty-five percent of the inputs the industry uses are imported.
The pessimistic reading of those numbers is that Mexico is a low-value-added assembly market. The strategic reading is different: there is a structural production deficit in a country with preferential commercial access to the world’s largest pharmaceutical market. For an operator with the capacity to manufacture under international standards, that combination — import substitution opportunity plus export platform — is a different proposition than simply cheap labor.
The proximity argument has real substance. Transit times by road from Mexico’s main manufacturing hubs to U.S. distribution centers run one to three days. From Asia by sea, the equivalent takes 30 to 45 days. That gap is not minor logistics: for products requiring cold-chain management, short shelf lives, or volatile demand, time in transit is part of the cost of capital. Beyond that, the USMCA eliminates tariffs for products meeting rules of origin, while Chinese competitors face 145% tariffs in 2025.
Haven’t set up a legal entity in Mexico yet? Start here: complete guide to incorporating a business in Mexico.
The Comparison That Actually Matters: Mexico vs. India, China, and Ireland
No CDMO location decision is made in isolation. The relevant question is not whether Mexico has advantages, but against whom and in which segments.
| Indicator | Mexico | India | China | Ireland |
|---|---|---|---|---|
| Fully burdened labor cost | USD 5.56–8.22/hr | USD 2.00–3.50/hr | USD 6.50–8.50/hr | USD 35–50/hr |
| FDA-approved plants | ~24 | 262+ | ~28 | ~50 |
| Transit time to U.S. | 1–3 days (road) | 30–45 days (sea) | 30–45 days (sea) | 7–10 days (air/sea) |
| Tariffs under U.S. trade agreement | 0% (USMCA) | ~0% (GSP, variable) | 145% (2025) | 0% (EU–U.S., sectoral) |
| BIOSECURE Act risk | None | None | High (named firms) | None |
| Share of U.S. pharma imports | ~1.5% | ~18% | ~13% | ~11% |
Sources: Wilson Center (2024), BLS, Reshoring Institute (2022), Pharmaceutical Technology, Morrison Foerster (January 2026), Grand View Research (May 2025).
India remains the highest-scale, lowest-cost CDMO destination: more than 262 FDA-approved plants, pharmaceutical exports of USD 30.4 billion in fiscal year 2025, and a generics supply chain built over four decades. No honest analysis would argue that Mexico can compete with India on scale or pure labor cost. But India imports between 70% and 80% of its APIs and key starting materials from China, meaning its apparent independence rests on a fragile link. China dominates global API production — it manufactures roughly 40% of the world’s supply — but the BIOSECURE Act and 145% tariffs have changed the risk calculus for any company with revenue tied to U.S. federal contracts.
Ireland is the reference standard for high-complexity biologics: it hosts 19 of the world’s top 20 biopharma companies, a mature EU-FDA regulatory ecosystem, and a 12.5% corporate tax rate. For first-tier biological molecules, Ireland remains hard to displace. For solid oral dosage forms, small-to-medium-volume sterile injectables, or secondary manufacturing and packaging oriented toward the North American market, Mexico offers a different equation.
Where Mexico Has Real Competitive Advantage — and Where It Doesn’t
Contract pharmaceutical manufacturing in Mexico is not uniform. The strengths are documented; so are the weaknesses.
Segments where competitive advantage is backed by installed capacity:
- Solid oral forms (tablets, capsules): multiple established operators — Liomont, Landsteiner, Kener, Sanfer, PiSA — with COFEPRIS GMP certifications and, in some cases, FDA approval. Laboratorios Liomont has a capacity of more than 120 million units per year.
- Sterile injectables: a segment in rapid expansion with documented investment. In 2025, Kener announced MXN 5.18 billion to triple its injectable capacity; PCI Pharma Services operates in Monterrey with sterile filling and lyophilization.
- Secondary manufacturing and packaging for North America: the model of upstream biologics in the U.S. with downstream packaging in Mexico already exists and has operational validation.
Segments where Mexico starts from a weak position:
- APIs and key starting materials: Mexico ranks as the 16th supplier of APIs to the United States. In only one pharmaceutical product does Mexico supply more than 75% of U.S. imports — India does so in 15, China in 32. The gap represents decades of investment.
- Advanced biologics and biosimilars: the ecosystem is nascent. Sanfer acquired Probiomed in 2022 to enter the biosimilars space; Genbio is building the first human plasma fractionation plant in Latin America. These are starting signals, not consolidated capability.
This distinction matters when structuring the investment case. An operator entering Mexico expecting to compete in high-volume APIs or gene therapies will need to build almost from scratch against competitors with three or four decades of accumulated advantage. One entering to capture solid oral and injectable manufacturing oriented toward the U.S. market, leveraging the USMCA and proximity, has a path with verifiable economic logic.
Three Risks That Financial Models Tend to Underestimate
COFEPRIS: The Reform Is Real, But So Is the Backlog
The new COFEPRIS leadership reduced its process categories from 287 to 106 and launched the DIGIPRiS digital platform. The Abbreviated Regulatory Pathway, effective September 1, 2025, sets a target timeline of 45 days for medicines previously approved by the FDA, EMA, or other recognized reference authorities. These are genuine advances.
The problem is the starting point. At the beginning of 2025, more than 1,500 marketing authorization applications were pending, some with delays exceeding 18 months. Chameleon Pharma Consulting’s realistic estimate for the complete process — from facility ready to commercial operations — is 18 to 36 months. The legal timelines are one thing; operational reality is another. Any financial model that uses “by-the-book” timelines (180 days for registration) without building in meaningful contingency will generate projections that will not survive the first year.
The Central Pharmaceutical Corridor and the Logistics Security Problem
In 2024, Mexico recorded 15,937 cargo theft incidents nationally, with 81% involving violence. In the first six months of 2025, the figure rose to more than 24,000 incidents. The State of Mexico accounts for 25% to 35% of incidents; Puebla for 19% to 23%. Those two states, along with Guanajuato and Jalisco, overlap directly with the country’s main pharmaceutical manufacturing corridors. The chemical industry reported a 100% increase in cargo theft incidents between 2023 and 2024 (ANIQ, 2024). Operating in Mexico without an explicit logistics security strategy — alternative routes, real-time monitoring, specialized insurers — is not a minor oversight; it is an operational gap with measurable financial consequences.
The Dysfunction of the Public Procurement System
For any CDMO that includes the Mexican government market in its investment thesis, recent history delivers a direct warning. The BIRMEX consolidated tender for 2025–2026 — the largest in Mexico’s history at MXN 338 billion — was declared null by the Anticorruption and Good Governance Secretariat after detecting overpricing of more than MXN 13 billion. Seventy-three percent of medicine categories went unawarded, generating shortages of insulin, oncologics, and antihypertensives. Supplier payment delays reach 18 months. None of these figures appear in investment promotion materials.
How the Tax Incentive Structure Works for New Entrants
Plan México, published in the Official Gazette on January 21, 2025, allocates MXN 28.5 billion to accelerated depreciation of new fixed assets, with rates between 41% and 91% depending on asset type, versus standard rates of 3% to 35%. Pharmaceutical and chemical products are explicitly listed as priority sectors. Assets acquired through September 30, 2030 qualify.
The IMMEX program allows the temporary duty-free import of raw materials and equipment for export-oriented manufacturing, with VAT certification that eliminates the 16% VAT on temporary imports. For an operator importing APIs from India or Europe and exporting finished product to the U.S., the IMMEX structure materially reduces the working capital tied up in customs.
For those who want to validate the market before committing direct investment, the shelter company model under IMMEX allows operations without establishing a Mexican legal entity in an initial phase. Several medical device manufacturers have already used this route to test real operating costs before committing to a greenfield project.
The Calculation That Defines the Decision
Mexico is neither the cheapest option nor the most sophisticated one. It is the closest option and the one most aligned with the commercial rules of the market that absorbs 88% of its exports. That has real value when the global supply chain is under simultaneous tariff, geopolitical, and regulatory pressure.
The practical question is not whether Mexico qualifies as a CDMO destination, but whether your organization has the capacity to navigate the gap between theoretical and actual regulatory timelines, the logistics security environment in the central corridor, and a public procurement system that — at least for now — should not appear in the denominator of any financial model. The companies that have entered with that clarity — PCI Pharma Services in Monterrey, Boehringer Ingelheim expanding its Mexico City plant, Indian manufacturers clustering in Hidalgo — did not come because Mexico was easy. They came because the USMCA, proximity, and geopolitical timing created a window. The window is real. What varies is whether your organization is equipped to go through it.